Summit Therapeutics (SMMT)
Health Care · Oncology biologics / bispecific antibodies
Oncology-focused biotech developing ivonescimab, a first-in-class bispecific antibody combining PD-1 immunotherapy with anti-VEGF anti-angiogenesis, with Phase III trials underway in lung and colorectal cancers.
What Summit Therapeutics does
Summit Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing medicinal therapies for oncology. The company's lead candidate is ivonescimab, a novel bispecific antibody that combines PD-1 immunotherapy with anti-VEGF anti-angiogenesis in a single molecule. Summit is developing ivonescimab in non-small cell lung cancer and colorectal cancer through multiple Phase III clinical trials across the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
Themes: ["Oncology / cancer therapeutics","Immunotherapy / PD-1 inhibitors","Anti-angiogenesis / VEGF inhibitors","Bispecific antibodies","Non-small cell lung cancer (NSCLC)","Colorectal cancer"]
Fundamentals
- Price$15.48 as of 2026-07-09 close
- Market cap$12.0B as of 2026-07-10
- 1-year return-31.8% as of 2026-07-09 close
- Net margin-9027.1% as of 2026-07-10
- ROE-291.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-1.36 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Success of ivonescimab depends on positive results in ongoing Phase III trials (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3); primary OS endpoint in HARMONi did not achieve statistical significance.","Funding risk: Company is unprofitable with significant negative net margin (-9027%) and must raise additional capital to fund License Agreement payments and ongoing R&D operations.","Regulatory and commercialization risk: Obtaining FDA approval and successfully commercializing ivonescimab requires meeting regulatory standards, establishing manufacturing partnerships, and competing against established immunotherapy and anti-angiogenesis competitors."]
Competitors & peers
- Merck (MSD) — Keytruda (pembrolizumab, PD-1)
- Bristol Myers Squibb — Opdivo (nivolumab, PD-1) and Bevyxxa combinations
- AstraZeneca — Imfinzi (durvalumab, PD-L1)
- Genmab / AstraZeneca — Tislelizumab (PD-1)
- Roche — Avastin (bevacizumab, anti-VEGF)
- Regeneron — Eylea (aflibercept, anti-VEGF)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.